Joincare(SH:600380) Zheng Quan Zhi Xing·2025-05-22 13:55Group 1 - The company intends to acquire 64.81% of Imexpharm Corporation (IMP) in Vietnam for approximately 5.73 trillion VND, equivalent to about 1.587 billion RMB, which represents 10.92% of the company's latest audited net assets [2][3] - The acquisition will be executed by LIAN SGP, a wholly-owned subsidiary of the company's controlling subsidiary, Lijun Group, and will not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [2][3] - The transaction has been approved by the company's board of directors and does not require shareholder approval [2][3] Group 2 - The target company, IMP, is a leading pharmaceutical enterprise in Vietnam, primarily engaged in the research, production, and sale of pharmaceuticals, including antibiotics and cardiovascular drugs, which align well with the existing product portfolio of Lijun Group [5][6] - The acquisition is expected to strengthen the company's international market presence and support its long-term strategy for sustainable development in the pharmaceutical sector [8] Group 3 - The transaction is subject to certain conditions, including regulatory approvals in Vietnam, and the company will comply with all necessary legal and regulatory requirements [3][10] - The acquisition will not involve personnel placement, land leasing, or debt restructuring, and upon completion, IMP will become a controlled subsidiary within the company's consolidated financial statements [8][9]